About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Abbott Developing Painkiller Spray for Dogs

By Jim Edwards | Aug 21, 2009

Abbott Labs is developing a painkiller spray for pet dogs, the company said. In a partnership with Velcera, Abbott is in clinical trials to bring Promist to market.

Promist is a transmucosal mist that is sprayed directly into a dog’s mouth. An NSAID painkiller is then absorbed through the animal’s cheek. The company said:

In addition to convenience for pet owners, Promist technology has several other advantages such as increased dosing confidence, faster absorption than delivery with a tablet or liquid and less concern with food interactions.

Anyone who has ever tried to get a dog to swallow a pill will be interested in trying this drug. Here’s what it’s like:

You show the hound two treats and give him one. Then you show him the pill. Then you jam your fingers into the sides of his jaws to get him to open up, and drop the pill as far back on his tongue as you can. Then you hold his mouth shut and begin a standoff in which the dog holds the pill in its mouth, refusing to swallow, even while you’re holding his snout closed. Dog eyes you suspiciously.

If he’s really clever, he’ll pretend to swallow, at which point you say “Good boy!” and then he hacks up a slimey pill onto your kitchen floor.

Repeat process until the dog gives in, and finally reward him with the second treat.

If Abbott makes the spray taste of bacon, it’s a surefire winner.

Image: The Fun Times Guide.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • NovaDel Receives Payment From Velcera Towards Its License, Development Agreement

    Pharmaceutical Business Review - 89 days 23 hours 46 minutes ago

    Agreement allows Velcera to use company's buccal spray delivery technology

  • Pharma Roundup: Glaxo, Cardio R&D, and Dynavax; Abbott, Ibis, and Isis; and More

    BNET Insight - 340 days 14 hours 32 minutes ago

    GlaxoSmithKline bets on cardiovascular research, Dynavax partnership — Big strategic moves this week at GSK. The drug maker has launched a three year, 15,000 patient clinical trial for darapladib, which it hopes will stop the plaque that clogs arteries. The trial will be expensive, but analysts at UBS say the drug could bring in upwards of $7...

  • Wyeth links with Japanese hospital network to speed up trials

    Scrip News - 147 days 39 minutes ago

    Wyeth has entered into a partnership with a network of hospitals in Japan to facilitate the conduct of local clinical trials with its development projects. The alliance is the first of its kind between a pharmaceutical company and the National

  • Pozen's shares soar as FDA approves study results

    Fierce Pharma - 298 days 19 hours 2 minutes ago

    Chapel Hill, NC-based Pozen saw its stock soar Thursday on the news that the FDA accepted its primary endpoint for two late-stage clinical trials PN 400, its arthritis drug. PN 400, which is being developed in partnership with AstraZeneca, combines the painkiller naproxen with AstraZeneca's Nexium (esomeprazole). Results from the trials...

  • Merck - Zetia: clinical trials, ain't they a bitch

    PharmaGossip - 137 days 10 hours 42 minutes ago

    Merck & Co. fell in New York trading after researchers halted a study comparing Abbott Laboratories’ cholesterol drug Niaspan with Zetia, sold by Merck and Schering- Plough Corp. The researchers said there were no safety concerns and chose to stop the study, called Arbiter 6 Halts, after a “prespecified, blinded interim analysis,”...

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here